Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19.
作者信息
Wu Dan-Na, Jiao Li-Rong, Li Guo-Fu, Yu Guo
机构信息
Department of Pharmacy, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Hainan, China.
Clinical Medical College, Yangzhou University, Yangzhou, 225009, China.
出版信息
Eur J Clin Pharmacol. 2022 Aug;78(8):1351-1352. doi: 10.1007/s00228-022-03319-w. Epub 2022 May 16.
Abstract
摘要
相似文献
1
Non-peer-reviewed data, effect measures, and meta-regression analysis on proton pump inhibitor use and COVID-19.关于质子泵抑制剂使用与2019冠状病毒病的非同行评审数据、效应量及元回归分析。
Eur J Clin Pharmacol. 2022 Aug;78(8):1351-1352. doi: 10.1007/s00228-022-03319-w. Epub 2022 May 16.
2
The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments.CYP2C19 基因多态性对质子泵抑制剂含有的幽门螺杆菌治疗的药代动力学/药效学的影响。
Curr Drug Metab. 2012 Nov;13(9):1303-12. doi: 10.2174/138920012803341393.
3
Proton pump inhibitor for treatment of Helicobacter pylori in patients with chronic renal failure: is it necessary?质子泵抑制剂用于治疗慢性肾衰竭患者的幽门螺杆菌感染：有必要吗？
Med Princ Pract. 2011;20(1):100. doi: 10.1159/000319927. Epub 2010 Dec 13.
4
Helicobacter pylori test and treat versus proton pump inhibitor: Role of H pylori in dyspepsia.幽门螺杆菌检测与治疗对比质子泵抑制剂：幽门螺杆菌在消化不良中的作用
BMJ. 2008 Apr 5;336(7647):735-6. doi: 10.1136/bmj.39535.515521.1F.
5
Diagnosis of Helicobacter pylori Infection in the Proton Pump Inhibitor Era.质子泵抑制剂时代幽门螺杆菌感染的诊断
Gastroenterol Clin North Am. 2015 Sep;44(3):507-18. doi: 10.1016/j.gtc.2015.05.001. Epub 2015 Jun 20.
6
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori.沃克与质子泵抑制剂根除幽门螺杆菌的比较
Kaohsiung J Med Sci. 2016 May;32(5):255-60. doi: 10.1016/j.kjms.2016.04.009. Epub 2016 May 21.
7
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.基于 vonoprazan 的三联疗法与基于药敏的质子泵抑制剂三联疗法根除幽门螺杆菌的非劣效性研究。
Ann Clin Microbiol Antimicrob. 2018 Jun 28;17(1):29. doi: 10.1186/s12941-018-0281-x.
8
Helicobacter pylori therapy in children: a focus on proton pump inhibitors.儿童幽门螺杆菌治疗：关注质子泵抑制剂。
Chemotherapy. 2011;57(1):85-93. doi: 10.1159/000323619. Epub 2011 Feb 23.
9
Comparative Effect of Proton-Pump Inhibitors on the Success of Triple and Quadruple Therapy for Helicobacter pylori Infection.质子泵抑制剂对幽门螺杆菌感染三联和四联疗法成功率的比较效果。
Dig Dis. 2020;38(5):408-414. doi: 10.1159/000504909. Epub 2020 Jan 7.
10
Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.荟萃分析：质子泵抑制剂或H2受体拮抗剂用于根除幽门螺杆菌
Aliment Pharmacol Ther. 2003 May 15;17(10):1229-36. doi: 10.1046/j.1365-2036.2003.01583.x.
本文引用的文献
1
Acid suppressant use in association with incidence and severe outcomes of COVID-19: a systematic review and meta-analysis.抑酸剂与 COVID-19 发病率和严重结局的关联：系统评价和荟萃分析。
Eur J Clin Pharmacol. 2022 Mar;78(3):383-391. doi: 10.1007/s00228-021-03255-1. Epub 2021 Nov 24.
2
Acid pH Increases SARS-CoV-2 Infection and the Risk of Death by COVID-19.酸性pH值会增加新型冠状病毒感染以及新冠肺炎的死亡风险。
Front Med (Lausanne). 2021 Aug 20;8:637885. doi: 10.3389/fmed.2021.637885. eCollection 2021.
3
COVID-19 in patients with hepatobiliary and pancreatic diseases: a single-centre cross-sectional study in East London.东伦敦单中心横断面研究：肝胆胰疾病患者中的 COVID-19。
BMJ Open. 2021 Apr 19;11(4):e045077. doi: 10.1136/bmjopen-2020-045077.
4
Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study.严重 COVID-19 与多种药物治疗和精神药物处方的关系：REACT-SCOT 病例对照研究。
BMC Med. 2021 Feb 22;19(1):51. doi: 10.1186/s12916-021-01907-8.
5
Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19.质子泵抑制剂对新型冠状病毒肺炎病程的影响分析
J Inflamm Res. 2021 Feb 5;14:287-298. doi: 10.2147/JIR.S292303. eCollection 2021.
6
Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea.韩国成年人中处方药与新冠病毒感染风险及严重程度的关联
Int J Infect Dis. 2021 Mar;104:7-14. doi: 10.1016/j.ijid.2020.12.041. Epub 2020 Dec 19.
7
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.COVID-19 患者住院前使用质子泵抑制剂与临床结局的关系
Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):137-141. doi: 10.1097/MEG.0000000000002013.
8
Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis.质子泵抑制剂会影响与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关的结果吗？一项荟萃分析。
Gut. 2021 Sep;70(9):1806-1808. doi: 10.1136/gutjnl-2020-323366. Epub 2020 Nov 10.
9
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤回：羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册分析
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
10
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
Zotero 插件